Clearside Biomedical

Clearside Biomedical Rule of 40

Delisted

The Rule of 40 of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -1,815.47 %. In the previous year, Rule of 40 was 216.48 % — a change of -938.64% (lower).

Rule of 40

-1,815.47 %

YoY

-938.64%

Last updated:

Rule of 40 of Clearside Biomedical is 2024 -1,815.47 % . Rule of 40 of Clearside Biomedical was 2023 216.48 % . It decreases by -938.64% lower compared to the previous year.

The Clearside Biomedical Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2017
-16,721.26 USD
Jan 1, 2018
-276,591.43 USD
Jan 1, 2019
5,737.02 USD
Jan 1, 2020
36.22 USD
Jan 1, 2021
272.81 USD
Jan 1, 2022
-2,372.20 USD
Jan 1, 2023
216.48 USD
Jan 1, 2024
-1,815.47 USD
The Clearside Biomedical Rule of 40 history
YEARRule of 40YoY
-1,815.47 %-938.64%
216.48 %-109.13%
-2,372.20 %-969.54%
272.81 %+653.24%
36.22 %-99.37%
5,737.02 %-102.07%
-276,591.43 %+1,554.13%
-16,721.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Rule of 40 of Clearside Biomedical is -1,815.47 % in 2024.

On Eulerpool you can find the complete historical development of Rule of 40 Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Clearside Biomedical

All Key Metrics — Clearside Biomedical